Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Lin

Showing results (141-150 of 152) with videos related to

Pageof 16
Sort By:
Nature Communications|December 7, 2018
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancerJingyi Liu, Zhibing Duan, Weijie Guo, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|August 8, 2014
International experience for laparoscopic major liver resectionIbrahim Dagher, Brice Gayet, Dimitrios Tzanis, et al.
European Heart Journal|June 22, 2014
Silencing of CCR2 in myocarditisFlorian Leuschner, Gabriel Courties, Partha Dutta, et al.
The Lancet. Oncology|May 17, 2026
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trialsShankar Siva, Muhammad Ali, Nicholas Hardcastle, et al.
Cancer Cell|April 17, 2014
Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasisWeiying Zhou, Miranda Y Fong, Yongfen Min, et al.
The Lancet. Oncology|February 29, 2024
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trialShankar Siva, Mathias Bressel, Mark Sidhom, et al.
The Lancet. Oncology|May 17, 2026
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 studyShankar Siva, David Pryor, Jarad Martin, et al.
Cognition|January 15, 2026
Finding our ROLE: How and why to reframe essentialist approaches to languageSavithry Namboodiripad, Ethan Kutlu, Anna Babel, et al.
Blood|September 20, 2022
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growthEugenio Morelli, Mariateresa Fulciniti, Mehmet K Samur, et al.
Journal of Chemical Information and Modeling|July 29, 2025
Recent Developments in Amber Biomolecular SimulationsDavid A Case, David S Cerutti, Vinícius Wilian D Cruzeiro, et al.
Pageof 16

Showing results (141-150 of 152) with videos related to

Sort By:
Pageof 16
Nature Communications|December 7, 2018
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancerJingyi Liu, Zhibing Duan, Weijie Guo, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|August 8, 2014
International experience for laparoscopic major liver resectionIbrahim Dagher, Brice Gayet, Dimitrios Tzanis, et al.
European Heart Journal|June 22, 2014
Silencing of CCR2 in myocarditisFlorian Leuschner, Gabriel Courties, Partha Dutta, et al.
The Lancet. Oncology|May 17, 2026
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trialsShankar Siva, Muhammad Ali, Nicholas Hardcastle, et al.
Cancer Cell|April 17, 2014
Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasisWeiying Zhou, Miranda Y Fong, Yongfen Min, et al.
The Lancet. Oncology|February 29, 2024
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trialShankar Siva, Mathias Bressel, Mark Sidhom, et al.
The Lancet. Oncology|May 17, 2026
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 studyShankar Siva, David Pryor, Jarad Martin, et al.
Cognition|January 15, 2026
Finding our ROLE: How and why to reframe essentialist approaches to languageSavithry Namboodiripad, Ethan Kutlu, Anna Babel, et al.
Blood|September 20, 2022
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growthEugenio Morelli, Mariateresa Fulciniti, Mehmet K Samur, et al.
Journal of Chemical Information and Modeling|July 29, 2025
Recent Developments in Amber Biomolecular SimulationsDavid A Case, David S Cerutti, Vinícius Wilian D Cruzeiro, et al.
Pageof 16